The Latest Cardiac and Vascular News
EurekaAI helps predict heart attacks through AI analysis of patient data LOS ALTOS, Calif., July 13, 2021 /PRNewswire/ — SymphonyAI, a leader in high-value enterprise AI solutions for key vertical sectors, announced today the expansion of a partnership with Semmelweis University Heart and Vascular Center, a leading research institution in East-Central Europe. […]
Highly specific HDAC6 inhibitors (HDAC6i) demonstrated improved cardiac function in mouse models of heart failure with preserved ejection in fraction (HFpEF) and genetic dilated cardiomyopathy (gDCM) Potential utility of HDAC6 as a target in heart disease was validated using Tenaya’s Precision Medicine platform HDAC6i product candidate TYA-11631 is currently in IND-enabling […]
Patient’s own tissue naturally turn device into living heart valves and may reduce need for re-interventions EINDHOVEN, the Netherlands & ZURICH–(BUSINESS WIRE)–Xeltis, a clinical-stage company with the most advanced polymer-based restorative cardiovascular devices, today announced that it has started the first-ever pivotal trial for a synthetic restorative pulmonary valve. To […]
LAGUNA HILLS, Calif., July 6, 2021 /PRNewswire/ — Adagio Medical, Inc., a leading innovator in catheter ablation technologies for atrial fibrillation (AF) and ventricular tachycardia (VT), today announced successful first-in-human use of ultra-low temperature cryoablation (ULTC) for the treatment of monomorphic VT. The two-hour mapping and ablation procedure was performed by Dr. Tom De Potter, MD, […]
Focused on preventing surgeries and use of medications, Modern Heart and Vascular Institute has an educational and holistic approach to heart and vascular care. HUMBLE, Texas, July 5, 2021 /PRNewswire/ — Modern Heart and Vascular Institute strives to provide the best care for patients, and do so with modern technology. The technologically advanced practice is equipped with a […]
TIANJIN, China, July 5, 2021 /PRNewswire/ — SINOMED, a leading international medical device company, today announced that they have teamed up with the National University of Ireland Galway (NUI Galway) to conduct a clinical trial for a new assessment method for stenting. The trial will employ the newly patented, HT Supreme® Healing-Targeted Drug-Eluting Stent (DES), […]
MONMOUTH JUNCTION, N.J., July 6, 2021 /PRNewswire/ — CytoSorbents Corporation (NASDAQ: CTSO) announces the full approval of its Investigational Device Exemption (IDE) application to conduct the pivotal STAR-T (Safe and Timely Antithrombotic Removal – Ticagrelor) double-blind, randomized, controlled trial (RCT) in the United States to support FDA regulatory clearance. This study is being performed under the previously announced FDA Breakthrough […]
– The EMPEROR-Preserved phase III trial met its primary endpoint and demonstrated significant risk reduction with Jardiance for the composite of cardiovascular death or hospitalization for heart failure in adults with heart failure with preserved ejection fraction – Heart failure with preserved ejection fraction has been classified as “the single […]
Ghent, BELGIUM – 6 July 2021 – Sequana Medical NV (Euronext Brussels: SEQUA, the “Company” or “Sequana Medical”), an innovator in the treatment of diuretic-resistant fluid overload in liver disease, malignant ascites and heart failure, today announces that the positive results from its RED DESERT study of alfapump DSR® (Direct Sodium Removal) which were presented at the Heart Failure […]
• Multicenter, double-blinded, controlled study designed to evaluate safety & efficacy of Lomecel-B intramyocardial injection in infants with HLHS • Funded by the National Heart, Lung and Blood Institute (Grant number 1UG3HL148318 and 1U24HL148316) in collaboration with Longeveron MIAMI, July 06, 2021 (GLOBE NEWSWIRE) — Longeveron Inc. (NASDAQ: LGVN) (“Longeveron” or […]
